Evidence map›Paper›PMID 31519698›Full record

ArticleCold Spring Harbor molecular case studies2019

Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a

Kazimierz O Wrzeszczynski, Sadia Rahman, Mayu O Frank, Kanika Arora, Minita Shah, Heather Geiger, Vanessa Felice, Dina Manaa, Esra Dikoglu, Depinder Khaira and 6 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Characteristics ofTherapeutic advances in medical oncology · 2025
    Article
  3. Article
  4. Review
  5. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Article
  6. BRAFScience advances · 2023
    Article
  7. Article
  8. Article
  9. Remarkable response ofGastroenterology report · 2022
    Article
  10. Article
  11. Article
  12. CaCancers · 2021
    Review
  13. Review
  14. Article
  15. Retrospective Case Series Analysis ofJCO precision oncology · 2021
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kazimierz O WrzeszczynskiNew York Genome Center, New York, New York 10013, USA.ORCID 0000-0001-6743-6149
Sadia RahmanNew York Genome Center, New York, New York 10013, USA.
Mayu O FrankLaboratory of Molecular Neuro-Oncology, The Rockefeller University, New York, New York 10065, USA.
Kanika AroraNew York Genome Center, New York, New York 10013, USA.
Minita ShahNew York Genome Center, New York, New York 10013, USA.
Heather GeigerNew York Genome Center, New York, New York 10013, USA.
Vanessa FeliceNew York Genome Center, New York, New York 10013, USA.
Dina ManaaNew York Genome Center, New York, New York 10013, USA.
Esra DikogluNew York Genome Center, New York, New York 10013, USA.
Depinder KhairaNew York Genome Center, New York, New York 10013, USA.
A Rao ChimpiriRenaissance School of Medicine, Department of Radiology, Stony Brook University, Stony Brook, New York 11794, USA.
Vanessa V MicheliniIBM Watson Health, New York, New York 10017, USA.
Vaidehi JobanputraNew York Genome Center, New York, New York 10013, USA.
Robert B DarnellNew York Genome Center, New York, New York 10013, USA.
Scott PowersRenaissance School of Medicine, Department of Pathology, Stony Brook University, Stony Brook, New York 11794, USA.
Minsig ChoiStony Brook Cancer Center, Stony Brook Medicine, Stony Brook, New York 11794, USA.

Funding

Transforming Translational Science and Education to Benefit Human HealthUL1TR000043 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY · 2012 to 2015
$26.8M
Supplement to Multigenic copy number alterationsR01CA217206 · NCI · STATE UNIVERSITY NEW YORK STONY BROOK · PI POWERS, SCOTT · 2017 to 2021
$2.8M
Howard Hughes Medical InstituteNCATS NIH HHS UL1 TR000043NCI NIH HHS R01 CA217206
6 · The paper itself

Abstract

The tumor genome of a patient with advanced pancreatic cancer was sequenced to identify potential therapeutic targetable mutations after standard of care failed to produce any significant overall response. Matched tumor-normal whole-genome sequencing revealed somatic mutations in

Indexed as

AdenocarcinomaAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungHumansImidazolesLung NeoplasmsMaleMutationOximesPancreatic NeoplasmsProtein Kinase InhibitorsProto-Oncogene Proteins B-rafRemission InductionWhole Genome SequencingBiomarkers, TumorBRAF protein, humandabrafenibImidazolesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafneoplasm of the pancreas

Identifiers

PMID31519698
PMCPMC6913137

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.